PACIFIC试验中度伐利尤单抗按肿瘤PD-L1表达分层的结局
PACIFIC试验探索性分析按肿瘤细胞PD-L1表达分层,评估度伐利尤单抗在不可切除III期NSCLC放化疗后未进展患者的疗效。451例可评估者中,TC≥25%占35%,<25%占65%。度伐利尤单抗在各亚组均改善PFS,除TC<1%外多数亚组改善OS,安全性相似。
要点
- 度伐利尤单抗在TC≥25%和<25%亚组均改善PFS,HR分别为0.41和0.59。
- OS获益见于多数亚组,但TC<1%亚组HR为1.14,不能得出稳健结论。
- 安全性在各PD-L1亚组间相似。
核心结论
- 度伐利尤单抗在各PD-L1亚组均观察到PFS获益,除TC<1%外多数亚组观察到OS获益。
- TC<1%亚组的OS结果受限于样本量和宽HR置信区间,无法得出稳健结论。
研究设计与样本
- PACIFIC试验的探索性分析,患者按2:1随机接受度伐利尤单抗10 mg/kg每2周或安慰剂,最长12个月。
- 共713例随机,709例接受至少1剂治疗(度伐利尤单抗473例,安慰剂236例)。
- 451例(63%)可评估PD-L1表达,采用免疫组化检测放化疗前样本,预设25%和事后1%肿瘤细胞 cut-off。
主要发现
- 截至2019年1月31日,中位随访33.3个月;PFS分析基于2017年2月13日数据截止。
- PFS的HR(95%CI)及中位值:TC≥25%为0.41(0.26-0.65),17.8 vs 3.7个月;TC<25%为0.59(0.43-0.82),16.9 vs 6.9个月;TC≥1%为0.46(0.33-0.64),17.8 vs 5.6个月;TC<1%为0.73(0.48-1.11),10.7 vs 5.6个月;TC 1%-24%为0.49(0.30-0.80),未达到 vs 9.0个月;未知为0.59(0.42-0.83),14.0 vs 6.4个月。
- OS的HR(95%CI)及中位值:TC≥25%为0.50(0.30-0.83),未达到 vs 21.1个月;TC<25%为0.89(0.63-1.25),39.7 vs 37.4个月;TC≥1%为0.59(0.41-0.83),未达到 vs 29.6个月;TC 1%-24%为0.67(0.41-1.10),43.3 vs 30.5个月;未知为0.60(0.43-0.84),44.2 vs 23.5个月;TC<1%为1.14(0.71-1.84),33.1 vs 45.6个月。
- 安全性在各亚组间相似。
关键数值与推荐
- PD-L1表达可评估者中,TC≥25%占35%,TC<25%占65%,TC≥1%占67%,TC<1%占33%,TC 1%-24%占32%。
临床怎么用
- 对于不可切除III期NSCLC放化疗后未进展患者,度伐利尤单抗的PFS获益在各PD-L1亚组中一致。
- PD-L1 TC<1%患者中OS未见获益,需个体化评估,不能依据该亚组数据排除治疗。
局限性
- PD-L1分析为探索性,非主要终点,样本量有限。
- TC<1%亚组的OS HR置信区间宽,结论不稳健。
- PD-L1状态未知患者占比较高,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression. PATIENTS AND METHODS: Patients were randomly assigned (2:1) to intravenous durvalumab 10 mg/kg every 2 weeks or placebo ≤12 months, stratified by age, sex, and smoking history, but not PD-L1 status. Where available, pre-CRT samples were tested for PD-L1 expression (immunohistochemistry) and scored at pre-specified (25%) and post hoc (1%) TC cut-offs. Treatment-effect hazard ratios (HRs) were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians). RESULTS: In total, 713 patients were randomly assigned, 709 of whom received at least 1 dose of study treatment durvalumab (n = 473) or placebo (n = 236). Some 451 (63%) were PD-L1-assessable: 35%, 65%, 67%, 33%, and 32% had TC ≥25%, <25%, ≥1%, <1%, and 1%-24%, respectively. As of 31 January 2019, median follow-up was 33.3 months. Durvalumab improved PFS versus placebo (primary-analysis data cut-off, 13 February 2017) across all subgroups [HR, 95% confidence interval (CI); medians]: TC ≥25% (0.41, 0.26-0.65; 17.8 versus 3.7 months), <25% (0.59, 0.43-0.82; 16.9 versus 6.9 months), ≥1% (0.46, 0.33-0.64; 17.8 versus 5.6 months), <1% (0.73, 0.48-1.11; 10.7 versus 5.6 months), 1%-24% [0.49, 0.30-0.80; not reached (NR) versus 9.0 months], and unknown (0.59, 0.42-0.83; 14.0 versus 6.4 months). Durvalumab improved OS across most subgroups (31 January 2019 data cut-off; HR, 95% CI; medians): TC ≥ 25% (0.50, 0.30-0.83; NR versus 21.1 months), <25% (0.89, 0.63-1.25; 39.7 versus 37.4 months), ≥1% (0.59, 0.41-0.83; NR versus 29.6 months), 1%-24% (0.67, 0.41-1.10; 43.3 versus 30.5 months), and unknown (0.60, 0.43-0.84; 44.2 versus 23.5 months), but not <1% (1.14, 0.71-1.84; 33.1 versus 45.6 months). Safety was similar across subgroups. CONCLUSIONS: PFS benefit with durvalumab was observed across all subgroups, and OS benefit across all but TC <1%, for which limitations and wide HR CI preclude robust conclusions.
引用
- Paz-Ares L, Spira A, Raben D, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020. PMID: 32209338. doi:10.1016/j.annonc.2020.03.287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。